Bristol-Myers Squibb Co. and ZymoGenetics Inc. Sept. 7 announced that they have signed a definitive agreement under which Bristol-Myers will acquire ZymoGenetics for approximately $885 million.
The companies said the transaction has been unanimously approved by the boards of directors of both companies.
Seattle-based ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.